Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK.

ABSTRACT:

Objective

The aim was to determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active psoriatic arthritis (PsA) who are tumour necrosis factor inhibitor (TNFi) naïve and without concomitant moderate-to-severe psoriasis, and who have responded inadequately to conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs).

Perspective and setting

The study took the perspective and setting of the UK National Health Service (NHS).

Methods

The model structure was a 3-month decision tree leading into a Markov model. Separate analyses based on the number of prior csDMARDs (one and  two or more) were conducted, with secukinumab 150 mg compared to standard of care (SoC) and TNFis, respectively, for each sub

SUBMITTER: Buchanan V 

PROVIDER: S-EPMC5999172 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature